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This review highlights advances made over the past 2
years in understanding the pathogenesis of systemic lupus
erythematosus (lupus). The criteria used in selecting the
articles include: 1) the study was performed using human
subjects as opposed to animal models; 2) the quality of
methods, data, and interpretation were acceptable; and 3)
a current body of literature exists supporting causality for
the mechanisms studied. Because lupus is a complex dis-
order, difficulties arise in distinguishing causal mecha-
nisms from secondary effects. The rationale for selecting
these reports rests in our present understanding of the
pathogenesis of this disease.
Current paradigms maintain that lupus develops in peo-
ple with a genetic predisposition, but also requires an
initiating event usually assumed to be environmental.
Many researchers are involved in identifying genes predis-
posing the patient to develop lupus (1,2), and a represen-
tative article characterizing potentially pathogenic Fc re-
ceptor (FcR) alleles is discussed. Although the initiating
event for most lupus cases is unknown, studies in both
human and murine systems indicate that T cells recogniz-
ing antigenic determinants in nucleosomes maintain and
possibly initiate the hallmark anti-DNA antibody response
(3), therefore a recent article examining this response in
lupus patients is discussed. Finally, a growing body of
literature indicates that the abnormal cell driving lupus is
the T lymphocyte, with numerous signaling and other
biochemical abnormalities reported in this profoundly dis-
turbed cell (4). One recent paper demonstrating a signaling
defect common to the majority of lupus patients is re-
viewed. Abnormalities in T cell DNA methylation have
also been identified in lupus patients and shown to cause
a lupus-like disease in animal models (5,6). Therefore a
report examining the mechanisms causing DNA hypo-
methylation in human lupus T cells is discussed.
The Fc receptor IIIA-158F allele is a major risk
factor for the development of lupus nephritis
among Caucasians but not non-Caucasians
(Arthritis Rheum, 2001) (7)
This retrospective study compares the frequency of 2 low
affinity FcR alleles, FcRIIA-131R and FcRIIIA-158F,
between 235 multiethnic lupus patients with biopsy
proven nephritis, and 352 multiethnic SLE patients with-
out evidence of renal involvement. The significant obser-
vation is that the presence of the FcRIIIA-158F allele, but
not the FcRIIA-131R allele, confers an increased risk of
nephritis among Caucasians. This study also implicates
additional genes beyond FcR alleles in disease suscepti-
bility, because an increased risk was not seen in other
ethnic populations, although small numbers may limit this
conclusion. The observation that the FcRIIIA-158F allele
confers susceptibility to lupus nephritis alone may pro-
vide useful prognostic information for Caucasian lupus
patients. However, the etiologic importance of this study is
that it identifies a candidate gene conferring an increased
risk for developing lupus nephritis.
Familial studies have established that genetic composi-
tion influences lupus susceptibility, although incomplete
concordance in identical twins implies the need for addi-
tional and presumably environmental factors. Previous
work has established that certain major histocompatibility
complex and complement alleles confer lupus susceptibil-
ity, and gender clearly plays a role. However, familial
studies demonstrate other multiple predisposing loci, and
the identity of these genes is unknown (1, 2). The present
study suggests that FcRIIIA-158F could be one of these
genes, although it is also possible that the risk comes from
a gene in close proximity to this allele, or an interacting
gene that differs in frequency between ethnic groups.
Nonetheless, there is theoretical rationale for proposing
low affinity FcR alleles as candidate genes. FcR are
involved in the clearance of IgG-containing immune com-
plexes, and the FcRIIIA-158F allele (with phenylalanine
at position 158) binds IgG1 and IgG3 less avidly than the
158V isoform (with valine at position 158). The decreased
binding affinity of the FcRIIIA-158F allele may result in
ineffective clearance of antigen–antibody complexes, re-
sulting in an increased susceptibility to immune complex-
mediated nephritis.
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Nucleosomes are major T and B cell autoantigens
in systemic lupus erythematosus
(Arthritis Rheum, 2000) (8)
This article examines the sensitivity and specificity of
immune responses to nucleosomes in lupus patients and
controls. A unique feature of this study is that T cell
responses as well as antibody reactivity are examined. The
authors reported that 54% of 26 patients with lupus had
proliferative T cell responses to nucleosomes, and none of
the 7 healthy controls or 10 patients with other autoim-
mune rheumatic diseases mounted a response. Using en-
zyme-linked immunosorbent assay, the authors found that
56% of 136 lupus sera reacted with nucleosomes, while
comparison with sera from 309 subjects with other inflam-
matory autoimmune and infectious conditions gave a
specificity of 97%. The specificity was significantly greater
than that of the anti-double-stranded DNA (dsDNA) re-
sponse (97% versus 79%), although the sensitivity was
lower (56% versus 70%), and others have reported a
higher specificity for the anti-dsDNA response in lupus
(9). The relatively low sensitivity of the T lymphocyte and
antibody responses may be due in part to the use of
chicken rather than human nucleosomes, because autore-
active T and B cells may not recognize chicken proteins in
the antigen preparation. Furthermore, T cells from patients
with active lupus are relatively anergic, and no specific
information is shown relating disease activity and the pro-
liferative response, so it is possible that disease activity
confounded the assays. However, this article does support
the concept that the autoimmune response in lupus in-
volves T and B cell reactivity to nucleosomal components.
The source of antigen initiating the lupus anti-DNA
response has long been a mystery, and nucleic acids from
exogenous agents such as viruses or bacteria are tradition-
ally invoked. However, DNA rarely if ever exists free of
bound proteins in vivo. Rather, it can be detected in the
form of nucleosomes in the peripheral blood of patients
with lupus presumably reflecting increased apoptosis, de-
creased clearance of apoptotic debris, or both (3). Interest-
ingly, injecting sufficient numbers of apoptotic cells into
mice will directly induce an anti-DNA response (10). Fur-
ther, kinetic evidence and specificity studies support the
concept that the nucleosome is the primary target of lupus
anti-histone and anti-DNA antibodies (3). Finally, nucleo-
some-reactive T cells that promote anti-DNA antibody syn-
thesis can be isolated from the peripheral blood of lupus
patients (11). Although these observations do not exclude
the possibility that infectious agents initiate the autoim-
mune response, nucleosomes appear to play an important
role in sustaining it and may provide the initiating antigen
as well. Together these reports support the important role
of the nucleosome as a stimulating antigen in human lupus.
High prevalence of T cell type I protein kinase A
deficiency in systemic lupus erythematosus
(Arthritis Rheum, 1999) (12)
Lupus T lymphocytes demonstrate numerous biochemical
abnormalities, and one of the better characterized is a
deficiency of protein kinase A type I (PKA-I). PKA-I is a
signaling molecule activated by cyclic AMP, and is re-
sponsible for the phosphorylation of several membrane
proteins. This article examines the prevalence of PKA-I
deficiency in lupus T cells and determines the relationship
between the enzyme deficiency and disease activity. The
authors report that T cells from 80% of 35 lupus patients
had decreased PKA-I enzyme activity, compared with 35
age-, sex-, and race-matched controls; that the defect was
stable over a period of 4 years in the 15 patients studied;
and that the decrease in enzyme activity was independent
of disease activity or treatment. Overall, PKA-I activity in
lupus T cells was approximately one-third the activity of
the controls. In other studies by the same group, the mech-
anism for the decreased activity has been explored and
appears to be multifactorial. Decreased transcription of
messenger RNA (mRNA) encoding subunits of this en-
zyme, transcript mutations resulting in abnormal mRNA,
and decreased translation of the mRNA into protein all
appear to be involved (13,14). It is also possible that allelic
differences contribute to the decreased expression, al-
though this remains to be established.
This report is significant because it identifies a T cell
signaling defect common to a majority of lupus patients
that is present independent of disease activity. This mo-
lecular defect thus provides a candidate mechanism for
some of the T cell abnormalities associated with lupus and
possibly contributes to its development. The role that
PKA-I plays in the T cell signaling cascade is not com-
pletely characterized, so the full impact of this enzyme
defect is not well understood. However, restoration of this
enzyme by transfection into lupus T cells has restored
interleukin-2 production, known to be decreased in lupus,
so the PKA-I signaling defect appears to have functional
significance (14). Given the evidence from other groups
(discussed below), altered expression of T cell genes in-
volved in signaling may well contribute to the pathogen-
esis of human lupus.
Decreased ras–mitogen-activated protein kinase
signaling may cause DNA hypomethylation in T
lymphocytes from lupus patients
(Arthritis Rheum, 2001) (15)
Studies involving patients with drug-induced lupus have
shown that hydralazine and procainamide are T cell DNA
methylation inhibitors, and adoptive transfer of T cells
made autoreactive by treatment with these or other DNA
methylation inhibitors causes a lupus-like disease in mu-
rine models. T cells from patients with active lupus have
decreased levels of DNA methylating enzymes and hypo-
methylated DNA (5), suggesting that the same process may
contribute to human lupus, but the mechanism causing the
DNA hypomethylation in lupus is unknown. This article
by Deng et al examines mechanisms that may contribute to
T cell DNA hypomethylation in lupus. DNA methyltrans-
ferase enzyme levels are regulated by signals transmitted
through the ras–mitogen-activated protein kinase (MAPK)
pathway; therefore, ras–MAPK signaling was examined in
lupus patients and controls. Signaling was decreased only
in lupus T cells, and the magnitude of the decrease was
directly proportional to disease activity. Inhibiting T cell
ras–MAPK signaling with a pharmacologic inhibitor de-
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creased DNA methyltransferase to the levels seen in lupus
T cells, and resulted in hypomethylated DNA. Although
the reason for the decreased signaling is unknown, this
study does demonstrate a specific pathway defect that may
account for the DNA hypomethylation seen in lupus T
cells. Because lupus T cells have multiple signaling de-
fects (discussed previously), a common pathway may link
abnormalities in the expression of a signaling molecule
such as PKA-I to decreased signaling through the ras–
MAPK pathway. Alternatively, a generalized defect in
other cellular functions such as protein synthesis or
mRNA editing may be responsible for a number of other-
wise unrelated signaling abnormalities.
How does DNA hypomethylation relate to lupus? The
DNA hypomethylation model assumes that the same genes
are affected by DNA hypomethylation induced by DNA
methylation inhibitors in vitro and in human lupus. In
support of this, the autoreactivity observed in T cells
treated with DNA methylation inhibitors is due in part to
overexpression of the adhesion molecule leukocyte func-
tion-associated antigen 1 (LFA-1), and LFA-1 is overex-
pressed on an autoreactive T cell subset in patients with
active lupus (16,17). Thus, the LFA-1 overexpression and
DNA hypomethylation may be linked to defective T cell
signaling, and contribute to disease pathogenesis. Further-
more, cells made autoreactive by DNA hypomethylation or
LFA-1 overexpression will spontaneously kill macro-
phages, releasing nucleosomal material (16). These pro-
cesses, together with a genetic predisposition from genes
like FcRIIIA-158F, may initiate an autoimmune response
that is then maintained by nucleosome-reactive T and B
lymphocytes, consistent with the conclusions of the other
articles discussed above.
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